Dataset opportunity
Fusixbiotech — Industrial Operations Dataset Opportunity
Moderate industrial operations dataset held by Fusixbiotech, usable for Industrial Monitoring and Forecasting.
Score
47.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
License
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global Pharma 4.0 Market = $11.9 Billion in 2023, CAGR 18.9%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Industrial Operations Dataset
Modality
Time Series
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
Medium
Accessibility
Partial
Legal
Owned by the company — licensing rights to clarify
Buyer persona
Industrial AI integrators
Fusixbiotech holds a comprehensive Industrial Operations Dataset derived from its advanced biomanufacturing processes, presented primarily as a Time Series modality. This data, including sensor readings and operational parameters from bioreactors, offers a granular view of biologic therapy production, making it exceptionally well-suited for training and validating Industrial Monitoring AI models for process optimization and predictive maintenance.
The business value of this data is highlighted by the Pharma 4.0 market, which was valued at USD 11.9 Billion in 2023 and is projected to grow at a CAGR of 18.9%. [6] While access requires careful negotiation due to Proprietary IP regarding hybrid viral constructs and shared manufacturing data with partners, the dataset's rarity and direct applicability offer a significant competitive advantage for AI developers in the high-growth biopharmaceutical sector. [6] ⚠ Diligence (valuable data, access to negotiate): Proprietary IP regarding hybrid viral constructs and modular vector design.; Preclinical data is highly sensitive and likely tied to pending patents.; Tech transfer agreements with CDMO partners (e.g., Recipharm) may involve shared manufacturing data. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves the holder owns a unique dataset from a modular biomanufacturing platform, capturing preclinical therapeutic performance. This is high-value process data for the rapidly expanding Pharma 4.0 market, which is projected to grow at nearly 19% annually. For industrial AI integrators, this dataset unlocks the ability to build and validate sophisticated predictive models for drug efficacy and process optimization, a critical need in modern biopharma R&D and manufacturing.
See dimension details ↓- Dataset Specificity78
dominant 'industrial_data', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity46
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/open (current)
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Industrial Monitoring
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand85
AI buyer demand is high, driven by the rapid growth of the Pharma 4.0 market (projected CAGR of 18.9%) and the critical need for real-world manufacturing data to train industrial optimization and predictive AI models. [6]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility56
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility66
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License70
ownership=owned, licensing=rights_unclear
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation73
3 data-appetite signals (3 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit58
⚠ review — Fusixbiotech is a preclinical-stage biotechnology company developing a cancer therapy platform, not a company with dormant operational data, making it a bad fit. Issues: The company's core business is developing and commercializing a proprietary oncolytic virus platform (InFUSE™) for cancer immunotherapy. [5, 8]; Their product is the therapy itself (FUSE102 is their lead candidate), which is a form of intelligence/biotech, not a by-product of a non-data business. [3, 7, ; The data they generate (preclinical, clinical trial data) is core to their R&D and regulatory approval process, not a 'dormant' or 'exhaust' dataset from an unr; The company is a pre-revenue R&D startup focused on drug development. [3, 9]
- Deep Qualification80
✓ pass — The target is a preclinical biotech developing oncolytic virus therapies; it does not sell data. It generates proprietary manufacturing data, but ownership is mixed due to a recent CDMO partnership, making data access complex.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
This is preclinical time-series data demonstrating therapeutic efficacy across various cancer models, essential for training predictive models for drug development.
Image collection
This is a collection of time-lapse microscopy images visually documenting cellular-level therapeutic effects, enabling advanced computer vision for process monitoring and validation.
Data catalog / marketplace
This describes the underlying modular platform from which the data originates, providing a structured dataset ideal for training AI to optimize processes for various therapeutic payloads.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Fusixbiotech Industrial Operations — a Moderate industrial operations dataset (Time Series modality) in the healthcare domain. Primary AI use-case: Industrial Monitoring. Market signal: Global Pharma 4.0 Market = $11.9 Billion in 2023, CAGR 18.9% (source: Market.us). Investment score 47.5/100 (confidence 0.49). Recommended action: License.
From the marketplace
Explore live data opportunities
Mt Nord — Maintenance Logs Dataset Opportunity
View opportunity →healthcareMeditek — Maintenance Logs Dataset Opportunity
View opportunity →healthcareCrs Medical — Maintenance Logs Dataset Opportunity
View opportunity →